Tests et analyse sur le microbiome

Assess the impact of your gynecological treatments on the vaginal microbiome

Vaginal and pharmaceutical microbiome

The vaginal microbiome: a key ecosystem for intimate health

The vaginal microbiome is a complex and dynamic ecosystem, dominated by bacteria of the genus Lactobacillus (L. crispatus, L. gasseri, L. iners, L. jensenii), representing up to 90% of the vaginal flora in healthy women (1,2).

These microorganisms perform essential functions:

  • Maintaining an acidic pH (≈4–4.5)
  • Protection against infections
  • Local immune support

When this balance is disrupted, dysbiosis can lead to:

  • Bacterial vaginosis: proliferation of anaerobes (Gardnerella vaginalis, Atopobium vaginae, Mycoplasma hominis), formation of a resistant biofilm, and elevated pH.
  • Candidiasis: Overgrowth of Candida albicans

These polymicrobial infections result in local symptoms (discharge, irritation, odor) and frequent recurrences due to biofilm resistance (1).

Maintaining the stability of the vaginal microbiome is a key challenge for pharmaceutical companies developing topical treatments, medical devices, and gynecological solutions.

Sources :
1. Romero R, Theis KR, Gomez-Lopez N, Winters AD, Panzer JJ, Lin H, et al. The Vaginal Microbiota of Pregnant Women Varies with Gestational Age, Maternal Age, and Parity. Microbiol Spectr. 17 août 2023;11(4):e0342922.
2. Abou Chacra L, Fenollar F, Diop K. Bacterial Vaginosis: What Do We Currently Know? Front Cell Infect Microbiol. 2021;11:672429.

Pourquoi tester vos produits sur le microbiome vaginal

At BYOME LABS, we study these interactions in vitro under conditions that faithfully reproduce the vaginal environment

Our models allow you to:

  • Cultivate strains representative of the vaginal microbiome,
  • Simulate specific dysbioses (vaginosis, candidiasis),
  • Evaluate the antimicrobial, regulatory, or restorative effects of your products,
  • Observe the formation and degradation of biofilms, particularly during treatment or after the application of targeted active ingredients.

These approaches provide valuable data for understanding the microbial mechanisms involved in vaginal pathologies and optimizing the selectivity and tolerability of pharmaceutical treatments.

At BYOME LABS, we support the R&D and regulatory teams of pharmaceutical companies in the design, validation, and efficacy demonstration of gynecological solutions.

Request a pharmaceutical vaginal microbiome analysis

The BYOME LABS approach

We:

  • Measure the impact of your treatments or devices on the vaginal microbiome,
  • Use customizable in vitro models: balance or dysbiosis, pH variations, biofilm, anaerobic flora,
  • Provide reliable and reproducible results that can be used for your regulatory and clinical dossiers,
  • Base our studies on culturomics and advanced microbiology approaches for a detailed analysis of bacterial diversity.

With 20 years of expertise in microbiology, we have mastered the culture of fastidious microorganisms (strict anaerobes, yeasts, Lactobacillus) and transform your scientific evidence into compelling arguments for research, regulatory bodies, and clinical practice.

Objective: to demonstrate the preventive, corrective or restorative action of your solutions on vaginal microbial homeostasis, in the service of feminine intimate health.

Request a pharmaceutical vaginal microbiome analysis

Évaluez l’impact des cosmetiques sur le microbiome

Byome Labs, French expert in pharmaceutical vaginal microbiome

Microbiology Laboratory and R&D Center – Clermont-Ferrand

We collaborate exclusively with:

• Pharmaceutical laboratories
• Manufacturers of dermatological medical devices
• Suppliers of active ingredients